ACIP Approves Changes in the 2017 Immunization Schedules (Children/Adolescents and Adults)

The Advisory Committee on Immunization Practices (ACIP) approved the Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger. More information concerning the changes can be found here.

The Advisory Committee on Immunization Practices (ACIP) also voted to approve the Recommended Adult Immunization Schedule for Adults Aged 19 Years or Older. More information concerning the changes can be found here. 

To download or print the new 2017 Immunization Schedules navigate to the CDC Immunization Schedules Webpage. 

 

Click here to download a PDF of the message highlighting the Children and Adolescent Immunization Schedule Changes

Click here to download a PDF of the message highlighting the Adult Immunization Schedule Changes

FluLaval® Can Now Be Administered to Children 6 Months and Older

FluLaval Only Pediatric Flu Vaccine Available Through VFC: Now Can Be Administered to Children 6 Months and Older

On November 18, 2016, the Food and Drug Administration approved an extension of the age range of quadrivalent FluLaval IIV to include children 6 through 35 months of age. FluLaval was previously approved for people 3 years of age and older.  The vaccine will be supplied by VFC for this indication in multi-dose vials. The dosage approved for children 6 through 35 months of age is 0.5 mL – the same dosage as for people 3 years of age and older.

ACIP has not yet issued a recommendation regarding the use of FluLaval in children 6 through 35 months of age. However, clinicians are free to use this and other vaccines in a manner consistent with their FDA labeling.  More information about FluLaval® and the updated recommendation can be found on the GSK Website.

Click here to download this message as a pdf

Vaccine Orders during the Holiday Season

Due to limited shipping availability by our distribution center, orders received after December 13th noon may not be shipped out until January 2017. You will still be able to submit orders for approval.

Please contact the VFC or VFAAR program if you need assistance.

Provider Education Coordinators – Jillian Brown and Mohan Nagaraja

DPHProviderhelp@phila.gov; 215-685-6872 or 215-685-6490

VFC Coordinator – Shumethia Seal

Shumethia.Seal@phila.gov; 215-685-6424

VFAAR Coordinator – Joani Schmeling

Joani.Schmeling@phila.gov; 215-685-6837

 

Click here to download this message as a pdf

ACIP Approves 2-Dose HPV Immunization

Two-Dose HPV Immunization Approved for Adolescents 11-14 Years of Age

The Advisory Committee on Immunization Practices (ACIP) and the U.S. Centers for Disease Control and Prevention (CDC) recommend that 11 through 14 year olds receive two doses of HPV vaccine at least six months apart rather than the previously recommended three doses.

Young adults aged 15 through 26 years will continue to need three doses of HPV vaccine.

For more information read the CDC’s press release: http://www.cdc.gov/media/releases/2016/p1020-hpv-shots.html

 

Click here for more information concerning details and tips for vaccinating adolescents.

Hiberix® Approved as a 3-dose Primary Vaccine

Effective immediately Hiberix® (Haemophilus influenza type b vaccine) is now available through the Philadelphia Vaccines For Children (VFC) Program.

Earlier this year, the Food and Drug Administration (FDA) approved Hiberix® for a 3-dose infant primary vaccination series at ages 2, 4, and 6 months. A single booster dose should be administered to children 15 through 18 months of age.

More information about Hiberix® and the updated recommendation can be found on the Vaccine Information Statement and the MMWR.

Click here to download this message as a pdf.